TY - JOUR
T1 - Sinonasal squamous cell carcinoma without clinical lymph node involvement
T2 - Which neck management is best?
AU - Castelnau-Marchand, Pauline
AU - Levy, Antonin
AU - Moya-Plana, Antoine
AU - Mirghani, Haïtham
AU - Nguyen, France
AU - Del Campo, Eleonor Rivin
AU - Janot, François
AU - Kolb, Frédéric
AU - Ferrand, François Régis
AU - Temam, Stéphane
AU - Blanchard, Pierre
AU - Tao, Yungan
N1 - Publisher Copyright:
© 2016, Springer-Verlag Berlin Heidelberg.
PY - 2016/8/1
Y1 - 2016/8/1
N2 - Objectives: The purpose of this work was to report outcomes of patients with nonmetastatic sinonasal squamous cell carcinoma (SNSCC) and to discuss the impact of elective neck irradiation (ENI) and selective neck dissection (SND) in clinically negative lymph node (N0) patients. Methods: Data from 104 nonmetastatic SNSCC patients treated with curative intent were retrospectively analysed. Uni- and multivariate analyses were used to assess prognostic factors of overall survival (OS) and locoregional control (LRC). Results: Median follow-up was 4.5 years. Eighty-five percent of tumours were stage III–IV. Treatments included induction chemotherapy (52.9 %), surgery (72 %) and radiotherapy (RT; 87 %). The 5‑year OS, progression-free survival, and LRC rates were 48, 44 and 57 %, respectively. Absence of surgery predicted a decrease of OS (hazard ratio [HR] 2.6; 95 % confidence interval [CI] 1.4–4.7), and LRC (HR 3.5; 95 % CI 1.8–6.8). Regional relapse was observed in 13/104 (13 %) patients and most common sites were level II (n = 12; 70.6 %), level III (n = 5; 29.4 %) and level Ib (n = 4; 23.5 %). Management of the neck in N0 patients (n = 87) included 11 % SND alone, 32 % ENI alone, 20 % SND + ENI and 37 % no neck treatment. In this population, a better LRC was found according to the management of the neck in favour of SND (94 % vs. 47 %; p = 0.002) but not ENI. Conclusion: SND may detect occult cervical positive nodes, allowing selective postoperative RT. ENI (ipsilateral level II, ±Ib and III or bilateral) needs to be proposed in selected patients, especially when SND has not been performed.
AB - Objectives: The purpose of this work was to report outcomes of patients with nonmetastatic sinonasal squamous cell carcinoma (SNSCC) and to discuss the impact of elective neck irradiation (ENI) and selective neck dissection (SND) in clinically negative lymph node (N0) patients. Methods: Data from 104 nonmetastatic SNSCC patients treated with curative intent were retrospectively analysed. Uni- and multivariate analyses were used to assess prognostic factors of overall survival (OS) and locoregional control (LRC). Results: Median follow-up was 4.5 years. Eighty-five percent of tumours were stage III–IV. Treatments included induction chemotherapy (52.9 %), surgery (72 %) and radiotherapy (RT; 87 %). The 5‑year OS, progression-free survival, and LRC rates were 48, 44 and 57 %, respectively. Absence of surgery predicted a decrease of OS (hazard ratio [HR] 2.6; 95 % confidence interval [CI] 1.4–4.7), and LRC (HR 3.5; 95 % CI 1.8–6.8). Regional relapse was observed in 13/104 (13 %) patients and most common sites were level II (n = 12; 70.6 %), level III (n = 5; 29.4 %) and level Ib (n = 4; 23.5 %). Management of the neck in N0 patients (n = 87) included 11 % SND alone, 32 % ENI alone, 20 % SND + ENI and 37 % no neck treatment. In this population, a better LRC was found according to the management of the neck in favour of SND (94 % vs. 47 %; p = 0.002) but not ENI. Conclusion: SND may detect occult cervical positive nodes, allowing selective postoperative RT. ENI (ipsilateral level II, ±Ib and III or bilateral) needs to be proposed in selected patients, especially when SND has not been performed.
KW - Chemotherapy
KW - Intensity-modulated radiotherapy
KW - Neck dissection
KW - Radiotherapy
KW - Treatment outcomes
UR - http://www.scopus.com/inward/record.url?scp=84975246135&partnerID=8YFLogxK
U2 - 10.1007/s00066-016-0997-5
DO - 10.1007/s00066-016-0997-5
M3 - Article
C2 - 27323752
AN - SCOPUS:84975246135
SN - 0179-7158
VL - 192
SP - 537
EP - 544
JO - Strahlentherapie und Onkologie
JF - Strahlentherapie und Onkologie
IS - 8
ER -